1085709-12-1

Basic information

• Product Name: methyl 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate
• Synonyms: methyl 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate
• CAS NO: 1085709-12-1
• Molecular Weight: 348.358
• Mol File: 1085709-12-1.mol

Chemical Properties

• CAS DataBase Reference: methyl 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate(1085709-12-1)
• EPA Substance Registry System: methyl 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate(1085709-12-1)

Safety Data

• Hazardous Substances Data: 1085709-12-1(Hazardous Substances Data)

Upstream product

• 121-33-5 vanillin 
• 1085709-24-5 1-(4-hydroxy-3-methoxyphenyl)tetrahydro-β-carboline-3-carboxylic acid 
• 1085709-16-5 methyl 1-(4-hydroxy-3-methoxyphenyl)tetrahydro-β-carboline-3-carboxylate 

Downstream Products

• 1401863-59-9 C₂₁H₂₀N₄O₃ 

Relevant articles and documents

Synthesis and biological evaluation of a novel class of β-carboline derivatives

In this study, several novel β-carboline derivatives, 1-(4-hydroxy-3-methoxyphenyl)-β-carboline-3-carboxyl-Trp-Trp-AA-OBzl compounds, were designed and synthesized as potential anticancer agents. Their in vitro cytotoxic activities were evaluated using me

Discovery of novel phosphatidylcholine-specific phospholipase C drug-like inhibitors as potential anticancer agents

Phosphatidylcholine–specific phospholipase C (PC-PLC) is a promising target for new anticancer treatment. Herein, we report our work in the discovery of novel drug-like PC-PLC inhibitors. Virtual screening led to the identification of promising hits from

COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME

Present invention refers to new compounds of formula I or II, its synthesis and its use in the treatment of metabolic syndrome, particularly for the treatment of type I or type II diabetes and/or metabolic syndrome or metabolic disease or metabolic disorders.

Synthesis and antitumoral activity of novel 3-(2-substituted-1,3,4-oxadiazol-5-yl) and 3-(5-substituted-1,2,4-triazol-3-yl) β-carboline derivatives

Several novel 1-substituted-phenyl β-carbolines bearing the 2-substituted-1,3,4-oxadiazol-5-yl and 5-substituted-1,2,4-triazol-3-yl groups at C-3 were synthesized and evaluated for their in vitro anticancer activity. The assay results pointed thirteen compounds with growth inhibition effect (GI50 50 values lying in the nanomolar concentration range (GI50 = 10 nM for both compounds). The 1-(N,N-dimethylaminophenyl)-3-(5-thioxo-1,2,4-triazol-3-yl) β-carboline (8g) was the most active compound, showing particular effectiveness on lung (GI50 = 0.06 μM), ovarian and renal cell lines. The potent anticancer activity presented for synthesized compounds 7a, 7h, and 8g, together with their easiness of synthesis, makes these compounds promising anticancer agents.